Loading...
•
Jun 30, 2022
Black Diamond Therapeutics Q2 2022 Earnings Report
Black Diamond Therapeutics reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $22.9 million for the second quarter of 2022. The company's cash, cash equivalents, and investments were approximately $160.9 million as of June 30, 2022, expected to be sufficient to fund operations into the third quarter of 2024.
Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
Advanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535
Continued IND-enabling studies of BDTX-4933
Cash, cash equivalents and investments of approximately $160.9 million as of June 30, 2022
Forward Guidance
Black Diamond has extended its cash runway, which is expected to be sufficient to fund its anticipated operating expenses and expenditure requirements into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...